Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Lieberman

Showing results (1011-1020 of 1,142) with videos related to

Pageof 115
Sort By:
Circulation Research|September 1, 1996
Cloning and characterization of rat density-enhanced phosphatase-1, a protein tyrosine phosphatase expressed by vascular cellsL G Borges, R A Seifert, F J Grant, et al.
The American Journal of Psychiatry|March 30, 2000
Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlatesR M Bilder, R S Goldman, D Robinson, et al.
Biological Psychiatry|September 6, 2005
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosisRichard S E Keefe, Larry J Seidman, Bruce K Christensen, et al.
Schizophrenia Research|September 21, 2005
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trialDel D Miller, Joseph P McEvoy, Sonia M Davis, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|April 11, 2017
Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesiaClement C Zai, Arun K Tiwari, Nabilah I Chowdhury, et al.
The Pharmacogenomics Journal|February 8, 2012
Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor geneN I Chowdhury, A K Tiwari, R P Souza, et al.
Schizophrenia Research|February 9, 2008
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1Jonathan M Meyer, Vicki G Davis, Donald C Goff, et al.
Molecular Psychiatry|March 3, 2010
Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugsD E Adkins, K Aberg, J L McClay, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|August 2, 2007
Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methodsJon McCLELLAN, Linmarie Sikich, Robert L Findling, et al.
The American Journal of Psychiatry|March 3, 2007
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE studyMarvin S Swartz, Diana O Perkins, T Scott Stroup, et al.
Pageof 115

Showing results (1011-1020 of 1,142) with videos related to

Sort By:
Pageof 115
Circulation Research|September 1, 1996
Cloning and characterization of rat density-enhanced phosphatase-1, a protein tyrosine phosphatase expressed by vascular cellsL G Borges, R A Seifert, F J Grant, et al.
The American Journal of Psychiatry|March 30, 2000
Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlatesR M Bilder, R S Goldman, D Robinson, et al.
Biological Psychiatry|September 6, 2005
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosisRichard S E Keefe, Larry J Seidman, Bruce K Christensen, et al.
Schizophrenia Research|September 21, 2005
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trialDel D Miller, Joseph P McEvoy, Sonia M Davis, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|April 11, 2017
Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesiaClement C Zai, Arun K Tiwari, Nabilah I Chowdhury, et al.
The Pharmacogenomics Journal|February 8, 2012
Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor geneN I Chowdhury, A K Tiwari, R P Souza, et al.
Schizophrenia Research|February 9, 2008
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1Jonathan M Meyer, Vicki G Davis, Donald C Goff, et al.
Molecular Psychiatry|March 3, 2010
Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugsD E Adkins, K Aberg, J L McClay, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|August 2, 2007
Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methodsJon McCLELLAN, Linmarie Sikich, Robert L Findling, et al.
The American Journal of Psychiatry|March 3, 2007
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE studyMarvin S Swartz, Diana O Perkins, T Scott Stroup, et al.
Pageof 115